A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models

One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4(+)) associates with lower overall and disease-free survival....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Haematologica
Asıl Yazarlar: Falgàs, Aïda, Pallarès, Victor, Unzueta, Ugutz, Céspedes, María Virtudes, Arroyo-Solera, Irene, Moreno, María José, Sierra, Jorge, Gallardo, Alberto, Mangues, María Antonia, Vázquez, Esther, Villaverde, Antonio, Mangues, Ramon, Casanova, Isolda
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Ferrata Storti Foundation 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049335/
https://ncbi.nlm.nih.gov/pubmed/31248974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.211490
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller